Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 14/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 13/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.61 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16802612 | 1.00 | MAPK8 (0.69) | MAPK8MAPK10MAPK9HPGDSDGAT2 | |
| SCHEMBL16802607 | 0.83 | MAPK8 (0.64) | MAPK8MAPK10MAPK9HPGDS | |
| SCHEMBL18148270 | 0.83 | MAPK8 (0.64) | MAPK8MAPK10MAPK9HPGDS | |
| SCHEMBL18148255 | 0.82 | MAPK8 (1.00) | MAPK8MAPK10MAPK9DGAT2FLT3 | |
| SCHEMBL16802579 | 0.82 | MAPK8 (1.00) | MAPK8MAPK10MAPK9DGAT2FLT3 | |
| SCHEMBL18148243 | 0.80 | MAPK8 (0.78) | MAPK8MAPK10MAPK9DGAT2FLT3 | |
| SCHEMBL16802581 | 0.80 | MAPK8 (0.78) | MAPK8MAPK10MAPK9DGAT2FLT3 | |
| SCHEMBL16802576 | 0.77 | MAPK8 (0.74) | MAPK8MAPK10HPGDSDGAT2HRH4 | |
| SCHEMBL16802595 | 0.76 | MAPK8 (1.00) | MAPK8MAPK10MAPK9 | |
| SCHEMBL16802651 | 0.75 | MAPK8 (1.00) | MAPK8MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK8 55/4885MAPK10 31/4885MAPK9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.